September 18, 2020
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
Media
September 16, 2020
Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares
September 15, 2020
GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)
September 14, 2020
Orexo commences patent infringement litigation against Sun Pharmaceutical
September 09, 2020
Orexo and GoGoMeds Partner to Bring Digital Therapies to Populations Battling Addiction and Depression with Limited Support Options
September 08, 2020
Oncopeptides further aligns the US and global organizational structure and appoints Mohamed Ladha as General Manager of the US Business Unit
September 08, 2020
Strongbridge Biopharma plc Provides Corporate Update
September 08, 2020
Strongbridge Biopharma plc Announces Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome
September 04, 2020
Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma – 495 patients included
September 03, 2020
Aprea Therapeutics to Present at Upcoming Investor Conferences
